Novartis India stake sale sparks 20% rally in 2026

What was announced and why it matters

Novartis AG has agreed to divest its controlling 70.68% stake in its listed subsidiary, Novartis India Limited, in a deal worth about ₹1,446 crore. The buyer is a consortium led by private equity firm ChrysCapital, along with WaveRise Investments Limited and Two Infinity Partners. The announcement quickly became a key market trigger because a change of control in a listed company requires a mandatory open offer for public shareholders under SEBI takeover rules.

For investors, the news is significant on two fronts. First, it marks Novartis’ decision to exit ownership of its India-listed arm. Second, the acquisition introduces a new promoter group with the option to raise its stake meaningfully through the open offer, potentially reshaping ownership concentration and governance.

Stock reaction: upper circuit and sharp gains

Shares of Novartis India surged on the announcement, with reports noting an 18% to around 20% rise. The stock hit the upper circuit, trading around ₹996 on Friday morning as investors reacted to the change-of-control transaction and the open-offer terms.

The open offer price was disclosed at ₹860.64 per share, which was described as a 3.64% premium to the previous day’s closing price of ₹830.45. While the open offer price is below the upper-circuit trading level mentioned in the reports, the mandatory offer and the new ownership plan appeared to drive buying interest.

Who is buying: ChrysCapital-led consortium

The acquiring consortium includes ChrysCapital Fund X, WaveRise Investments Limited, and Two Infinity Partners. ChrysCapital is described as one of India’s largest private equity firms and is known for backing companies such as Intas Pharma, Eris Lifesciences, Corona Remedies, and La Renon. The Novartis India transaction is also described as ChrysCapital’s first majority deal in the Indian pharma space.

Market chatter in the report said the asset had earlier been eyed by players such as Dr Reddy’s and Alkem. However, the definitive agreement announced is with the ChrysCapital-led group.

Deal structure: sale of 70.68% and a 26% open offer

Novartis AG is selling its entire 70.68% shareholding in Novartis India. The definitive agreement covers the sale of 1,74,50,680 equity shares held by Novartis AG. The underlying transaction value for this stake was disclosed at ₹1,445.89 crore.

Following the share purchase agreement, the acquirers announced an open offer to buy up to an additional 26% of Novartis India’s voting share capital, equivalent to 64,19,608 equity shares. If fully subscribed, the open offer would involve total cash consideration of ₹552.49 crore.

Axis Capital is managing the open offer, as disclosed.

Key numbers at a glance

Price terms and disclosed variations

The open offer price is clearly stated at ₹860.64 per share. One report also noted that WaveRise would purchase the bulk at ₹860.64 per share, while ChrysCapital-linked entities would acquire smaller portions at about ₹701.25 per share, based on the filing cited there.

The open offer, however, is at ₹860.64 per share for public shareholders. This is the relevant benchmark for minority investors considering tendering shares, subject to the formal open offer schedule and conditions.

What changes after the transaction: promoter status and shareholding scenarios

Upon completion, the ChrysCapital-led consortium will become the new promoter of Novartis India. Novartis AG will cease to be the promoter and will be reclassified under the public shareholder category.

The disclosures also describe two ownership outcomes tied to open-offer participation. If the open offer is fully subscribed, the new promoters’ combined holding would rise to 96.68%. If no shares are tendered into the open offer, the promoters’ stake would remain at 70.68%.

A separate disclosure in the report outlined a possible post-acquisition shareholding split, stating that if fully subscribed the shareholding would see WaveRise hold 72.78%, ChrysCapital Fund X 17.33%, and Two Infinity Partners 6.57%. It also cited a low-participation scenario where WaveRise would still hold 56.45%, ChrysCapital 10.32%, and Two Infinity Partners 3.91%.

Background: strategic review and Novartis’ stated focus

The transaction follows a strategic review initiated by Novartis earlier, and the reports say the objective was to focus on high-value, innovation-led medicines. In practical terms, the sale represents a clean exit from the listed Indian arm, rather than a partial dilution.

The announcement also aligns with the description that Novartis is streamlining global operations, as referenced in one of the cited reports.

Market impact: what investors should watch next

In the near term, the key market inputs are the open offer process and closing timeline. The companies stated the transaction is subject to satisfaction of conditions precedent and is expected to close in Q3 2026. Until closing, investors will track regulatory clearances, the open offer timetable, and detailed terms contained in stock exchange filings.

For public shareholders, the practical decision point is whether to participate in the open offer at ₹860.64 per share, factoring in prevailing market price movements and the final offer schedule. For the broader pharma market, the deal is a notable example of private equity taking a majority position in a listed Indian pharma company.

Why this deal stands out

The most immediate takeaway is that Novartis is exiting ownership of Novartis India through a controlling stake sale, and the market repriced the stock sharply on the news. The second is that the consortium has a pathway to take ownership as high as 96.68% if the open offer is fully subscribed, implying potential for high promoter concentration.

The next confirmed milestone is execution: completion is targeted for Q3 2026, subject to the stated conditions, with the open offer managed by Axis Capital.